8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2
Author:
P. Tomasini,A. Blasco Cordellat,C. Dooms,M. Mackean,A. Bearz,O.J. Juan Vidal,D.M. Kowalski,K. Stencel,R. Califano,P. Hulo,V. Surmont,A. Zer,J. Schuchard,J. Diels,P-L. Chu,S. Shah,B. Diorio,A. Garvin,J.M. Bauml,E. Felip